Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
A calcineurin inhibitor is an immunomodulating medicine that blocks the enzyme calcineurin. Calcineurin normally helps activate T lymphocytes and promotes production of immune-signaling proteins such as interleukin-2. Inhibiting this pathway reduces selected immune responses. Major examples are cyclosporine, tacrolimus, and the topical medicine pimecrolimus.
read more about calcineurin inhibitor ...Systemic calcineurin inhibitors are used to prevent rejection after organ transplantation. They are also used for selected autoimmune or inflammatory conditions when their benefits outweigh the risks. Topical tacrolimus and pimecrolimus treat certain cases of atopic dermatitis, while ophthalmic cyclosporine products are used for selected ocular surface conditions. The formulation, dose, and monitoring differ greatly among these uses.
Cyclosporine binds to cyclophilin, while tacrolimus and pimecrolimus bind to FK506-binding proteins. These drug-protein complexes inhibit calcineurin and prevent activation of nuclear factor of activated T cells. Reduced signaling decreases transcription of interleukin-2 and other cytokines needed for T-cell activation. The result is suppression of immune and inflammatory activity.
Systemic products are available in oral and intravenous formulations, and topical products are applied to the skin or eye according to their labels. Cyclosporine formulations are not always interchangeable because absorption can differ. Tacrolimus and cyclosporine commonly require blood-concentration monitoring after transplantation. Doses are adjusted according to clinical response, kidney function, adverse effects, interactions, and measured drug levels.
Systemic calcineurin inhibitors can cause kidney injury, high blood pressure, tremor, headache, electrolyte abnormalities, infection, and increased malignancy risk. Tacrolimus can contribute to high blood glucose, while cyclosporine can cause gum overgrowth or increased hair growth. Both medicines have numerous cytochrome P450 3A and transporter interactions, including clinically significant interactions with grapefruit products and selected antifungals or antibiotics. Close laboratory and clinical monitoring is required.
No. They suppress immune activity through calcineurin signaling rather than through glucocorticoid receptors. They can be used with or instead of corticosteroids in selected treatment plans.
Systemic tacrolimus and cyclosporine have narrow therapeutic ranges and variable absorption. Blood-level monitoring helps balance rejection prevention or disease control against toxicity.
Yes. Nephrotoxicity is an important risk of systemic tacrolimus and cyclosporine. Kidney function, blood pressure, electrolytes, and drug exposure require monitoring.
Yes. Grapefruit can inhibit enzymes and transporters that help process tacrolimus or cyclosporine, causing drug levels to rise. Patients should follow the product-specific food restrictions.
Calcineurin Inhibitors. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK558995/. Date Accessed August 6, 2026.
Tacrolimus. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK544318/. Date Accessed August 6, 2026.
Tacrolimus Capsules: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46ac55cf-d85e-4c34-bb33-f49e078c4a03. Date Accessed August 6, 2026.
Cyclosporine Capsules, USP (Modified): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5baaf78c-90f6-abcf-52c8-814490f3cf9f&type=display. Date Accessed August 6, 2026.
Pimecrolimus Cream, 1%: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6601e43e-ce7d-446a-8568-8e7b24b86f06. Date Accessed August 6, 2026.